The Clorox Company
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-64.4% vs price
Base Case (Median)
-28.6% vs price
Bull Case (75th pct.)
-21.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-1117.44 | -1154.8% | High (40%) |
| PE Comparable | $88.40 | -16.6% | Medium (25%) |
| Growth Trajectory DCF | $77.31 | -27.0% | Medium (20%) |
| Graham Number | $8.94 | -91.6% | High (80%) |
| EV/EBITDA | $75.63 | -28.6% | Medium (20%) |
| EV/FCF | $66.52 | -37.2% | Medium (20%) |
| Earnings Power Value | $257.03 | 142.6% | High (70%) |
Based on 7 out of 8 methods, CLX appears overvalued at the current price of $105.94. The base case fair value of $75.63 implies 28.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.